Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma

Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).

Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma

When selecting between an adjuvant targeted therapy or immunotherapy for a patient with melanoma, it’s important to consider several factors, including the biologic behavior of the tumor, any comorbidities, toxicities, and patient concerns, according to Reinhard Dummer, MD.

Improved dermoscopy training in residency should be prioritized

Dermoscopy training and education should be prioritized in resident education to increase melanoma detection, according to a study published in JAMA Dermatology.

Low-Dose IL-2 Shows Promise in Colitis

Low doses of the recombinant T-cell growth factor interleukin 2 (IL-2, aldesleukin, Proleukin) were well tolerated among patients with moderate-to-severe ulcerative colitis in a small 8-week study, with only one patient being withdrawn because of a dose-limiting toxicity, a researcher reported.